Nyxoah launches Genio bilateral neurostimulation system in Netherlands
Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.
The first implants were completed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen, marking a significant milestone in the company’s European rollout.
The Genio system is designed to provide bilateral nerve stimulation as an alternative to traditional CPAP treatments for obstructive sleep apnea (OSA) patients who struggle to tolerate CPAP.
Notably, the device does not require an implanted battery and offers full-body MRI compatibility with both 1.5T and 3T machines.
Additionally, it features an externally powered activation chip that allows for future upgrades, adding long-term value for patients.
Nyxoah emphasized that the successful early implants validate Genio’s potential as a sustainable treatment option for sleep apnea sufferers, providing a non-invasive and easily upgradeable solution.
The company views the Netherlands launch as an essential step in expanding its presence across Europe and offering a next-generation treatment for the millions of OSA patients who need alternatives to traditional CPAP therapy
More from United States
Lamar raises 2026 AFFO outlook to $8.97
Lemonade posts $336 million Q3 revenue, narrows loss
BD reveals $5.27 billion Q4 revenue, raises 2027 outlook
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
